Applied DNA Sciences (NASDAQ:APDN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research report released on Sunday morning. The firm issued a hold rating on the technology company’s stock.

Separately, HC Wainwright lowered their target price on shares of Applied DNA Sciences from $2.00 to $1.50 and set a buy rating for the company in a research note on Friday, February 9th.

Applied DNA Sciences Stock Performance

APDN stock opened at $0.34 on Friday. The stock has a market capitalization of $5.83 million, a P/E ratio of -0.64 and a beta of 0.07. Applied DNA Sciences has a one year low of $0.31 and a one year high of $1.86. The company has a 50 day moving average price of $0.49 and a two-hundred day moving average price of $0.67.

Applied DNA Sciences (NASDAQ:APDN) last released its earnings results on Thursday, February 8th. The technology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.22. The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $0.70 million. Applied DNA Sciences had a negative net margin of 80.14% and a negative return on equity of 159.93%. Research analysts forecast that Applied DNA Sciences will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Applied DNA Sciences

Several institutional investors have recently made changes to their positions in APDN. AMH Equity Ltd grew its stake in shares of Applied DNA Sciences by 76.3% during the 3rd quarter. AMH Equity Ltd now owns 587,232 shares of the technology company’s stock valued at $711,000 after buying an additional 254,232 shares during the period. Vanguard Group Inc. grew its stake in shares of Applied DNA Sciences by 67.3% during the 3rd quarter. Vanguard Group Inc. now owns 353,050 shares of the technology company’s stock valued at $399,000 after buying an additional 142,000 shares during the period. Two Sigma Investments LP purchased a new stake in shares of Applied DNA Sciences during the 3rd quarter valued at $146,000. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of Applied DNA Sciences during the 4th quarter valued at $61,000. Finally, State Street Corp grew its stake in shares of Applied DNA Sciences by 180.5% during the 3rd quarter. State Street Corp now owns 75,677 shares of the technology company’s stock valued at $86,000 after buying an additional 48,700 shares during the period. 22.22% of the stock is owned by hedge funds and other institutional investors.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.